PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL) AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES

被引：0

作者：

Davids, M. S. ^{[1
]}

Seymour, J. F. ^{[2
]}

Gerecitano, J. F. ^{[3
]}

Kahl, B. S. ^{[4
]}

Pagel, J. M. ^{[5
]}

Wierda, W. G. ^{[6
]}

Anderson, M. A. ^{[7
,8
]}

Rudersdorf, N. K. ^{[9
]}

Gressick, L. A. ^{[9
]}

Montalvo, N. P. ^{[9
]}

Yang, J. ^{[9
]}

Zhu, M. ^{[9
]}

Dunbar, M. ^{[9
]}

Cerri, E. ^{[9
]}

Enschede, S. H. ^{[9
]}

Humerickhouse, R. A. ^{[9
]}

Roberts, A. W. ^{[7
,8
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Wisconsin, Madison, WI 53706 USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Texas Houston, Houston, TX USA

[7] Royal Melbourne Hosp, Melbourne, Vic, Australia

[8] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia

[9] AbbVie, N Chicago, IL USA

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S1348

引用

页码：525 / 525

页数：1

共 50 条

[1] Phase I Study of ABT-199 (GDC-0199) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Responses Observed in Diffuse Large B-Cell (DLBCL) and Follicular Lymphoma (FL) at Higher Cohort Doses
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (08) : 18 - 19
[2] Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Davids, Matthew Steven
Seymour, John Francis
Gerecitano, John F.
Kahl, Brad S.
Pagel, John M.
Wierda, William G.
Anderson, Mary Ann
Rudersdorf, Nikita
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Jianning
Zhu, Ming
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Gerecitano, John F.
Roberts, Andrew W.
Seymour, John F.
Wierda, William G.
Kahl, Brad S.
Pagel, John M.
Puvvada, Soham
Kipps, Thomas J.
Anderson, Mary Ann
Dunbar, Martin
Zhu, Ming
Gressick, Lori
Wagner, Lindsay
Kim, Su Young
Enschende, Sari Heitner
Humerickhouse, Rod A.
Davids, Matthew S.
BLOOD, 2015, 126 (23)
[4] The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
de Vos, Sven
Flowers, Christopher R.
Wang, Ding
Swinnen, Lode J.
Fowler, Nathan
Reid, Erin
Gifford, Maryella
D'Amico, Diane
Dunbar, Martin
Zhu, Ming
Yang, Jianning
Enschede, Sari H.
Ricker, Justin L.
Chien, David
Humerickhouse, Rod A.
Kozloff, Mark
BLOOD, 2014, 124 (21)
[5] A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
de Vos, Sven
Swinnen, Lode
Kozloff, Mark
Wang, Ding
Reid, Erin
Nastoupil, Loretta
Fowler, Nathan
Cordero, Jaclyn
D'Amico, Diane
Diehl, Susan
Dunbar, Martin
Zhu, Ming
Wong, Shekman
Enschede, Sari Heitner
Chien, David
Humerickhouse, Rod A.
Flowers, Christopher
BLOOD, 2015, 126 (23)
[6] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
Davids, Matthew Steven
Seymour, John Francis
Gerecitano, John F.
Kahl, Brad S.
Pagel, John M.
Wierda, William G.
Anderson, Mary Ann
Darden, David E.
Nolan, Cathy E.
Gressick, Lori A.
Yang, Jianning
Chyla, Brenda J.
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew W.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients
Davids, Matthew S.
Seymour, John F.
Gerecitano, John F.
Kahl, Brad S.
Pagel, John M.
Wierda, William G.
Anderson, Mary-Ann
Rudersdorf, Nikita K.
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Jianning
Busman, Todd A.
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew W.
BLOOD, 2013, 122 (21)
[8] THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA AND OTHER NON-HODGKIN LYMPHOMAS
Davids, M.
Seymour, J.
Gerecitano, J.
Kahl, B.
Pagel, J.
Wierda, W.
Anderson, M.
Darden, D.
Nolan, C.
Gressick, L.
Yang, J.
Chyla, B.
Busman, T.
Graham, A.
Cerri, E.
Enschede, S.
Humerickhouses, R.
Roberts, A.
HAEMATOLOGICA, 2013, 98 : 355 - 356
[9] Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
Hawkes, Eliza Anne
Manos, Kate
Chong, Geoffrey
Palmer, Jodie
MacManus, Michael Patrick
Keane, Colm
Scott, Andrew Mark
Shortt, Jake
Ritchie, David
Churilov, Leonid
Johnston, Laura
Witkowski, Tom
Barraclough, Allison Anne
Lee, Sze Ting
Lin, Wendi
Koldej, Rachel
Khor, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
Herrera, A.
Goy, A.
Mehta, A.
Ramchandren, R.
Pagel, J.
Svoboda, J.
Guan, S.
Hill, J.
Kwei, K.
Liu, E.
Phillips, T.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18

← 1 2 3 4 5 →